Apogee Therapeutics Statistics Share Statistics Apogee Therapeutics has 58.57M
shares outstanding. The number of shares has increased by 1.79%
in one year.
Shares Outstanding 58.57M Shares Change (YoY) 1.79% Shares Change (QoQ) 0.05% Owned by Institutions (%) 99.99% Shares Floating 47.49M Failed to Deliver (FTD) Shares 179 FTD / Avg. Volume 0.02%
Short Selling Information The latest short interest is 9.12M, so 15.31% of the outstanding
shares have been sold short.
Short Interest 9.12M Short % of Shares Out 15.31% Short % of Float 31.82% Short Ratio (days to cover) 16.13
Valuation Ratios The PE ratio is -13.73 and the forward
PE ratio is -6.68.
Apogee Therapeutics's PEG ratio is
-0.14.
PE Ratio -13.73 Forward PE -6.68 PS Ratio 0 Forward PS n/a PB Ratio 3.49 P/FCF Ratio -14.51 PEG Ratio -0.14
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Apogee Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 18.55,
with a Debt / Equity ratio of 0.02.
Current Ratio 18.55 Quick Ratio 18.55 Debt / Equity 0.02 Debt / EBITDA -0.05 Debt / FCF -0.07 Interest Coverage 0
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-929.32K Employee Count 196 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax -18K Effective Tax Rate 0.01%
Stock Price Statistics The stock price has increased by -19.85% in the
last 52 weeks. The beta is 1.43, so Apogee Therapeutics's
price volatility has been higher than the market average.
Beta 1.43 52-Week Price Change -19.85% 50-Day Moving Average 38.59 200-Day Moving Average 39.57 Relative Strength Index (RSI) 51.32 Average Volume (20 Days) 841,166
Income Statement
Revenue n/a Gross Profit -189K Operating Income -216.87M Net Income -182.15M EBITDA -216.87M EBIT -182.13M Earnings Per Share (EPS) -3.3
Full Income Statement Balance Sheet The company has 141.79M in cash and 11.83M in
debt, giving a net cash position of 129.96M.
Cash & Cash Equivalents 141.79M Total Debt 11.83M Net Cash 129.96M Retained Earnings -305.92M Total Assets 657.77M Working Capital 484.57M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -171.17M
and capital expenditures -1.15M, giving a free cash flow of -172.33M.
Operating Cash Flow -171.17M Capital Expenditures -1.15M Free Cash Flow -172.33M FCF Per Share -3.12
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
